Tiziana jumps as intranasal spray well-tolerated in multiple sclerosis patient

Tiziana Life Sciences

10/03/2022 12:52

** U.S.-listed shares of biotech co  TLSA.O  rise 20.2% to
89 cents premarket - set to snap their three-day losing streak
if gains hold  
    ** Co says its intranasal spray, Foralumab, was
well-tolerated in one patient suffering from a type of multiple
sclerosis after 6 months of therapy  urn:newsml:reuters.com:*:nGNX45fNZs
    ** Patient suffering from secondary progressive multiple
sclerosis (SPMS) began treatment with intranasal foralumab which
stabilized course of disease, says co 
    ** SPMS is a debilitating neurological condition in which
the immune system eats away at the protective covering of nerves
    ** TLSA says data shows treatment with foralumab, given
thrice weekly followed by one week off therapy, also reduced
activity of molecules known as cytokines linked to brain
inflammation
    ** Co says received FDA approval to continue treating
patient for an additional 6 months, allowed second patient to
receive the antibody therapy
    ** Up to Wednesday's close, TLSA was down 23.7% YTD 

    
    
    
    

 (Reporting by Bhanvi Satija in Bengaluru)
 ((Bhanvi.Satija@thomsonreuters.com; Outside U.S. +91
9873062788;))